Key result
Disulfiram inhibited cardiomyocyte viability and promoted apoptosis, with cardiomyocytes demonstrating greater sensitivity to the drug than cancer cells.
Why the study?
Does disulfiram inhibit viability and induce apoptosis in cardiomyocytes?
Does disulfiram inhibit viability and induce apoptosis in cardiomyocytes?
Disulfiram exhibits potential cardiotoxic effects by inhibiting viability and inducing apoptosis in cardiomyocytes, though PEG may serve as a promising solvent to mitigate these adverse effects.
Answers are grounded in this paper and cite their sources.
May signal disulfiram cardiotoxicity risk; animal data leave open human relevance and mitigation.
Disulfiram (DSF), widely used for treating alcohol abuse, is a promising antitumour drug that inhibits tumour cell viability, reverses cancer drug resistance and induces apoptosis. However, its potential side effects on cardiomyocytes remain unknown. This study demonstrated that DSF can not only inhibit cardiomyocyte viability and activity but also promote cell apoptosis. Furthermore, we revealed that cardiomyocytes were more sensitive to DSF than cancer cells. Moreover, the expression of STAT3, a key regulator of cardiomyocyte viability, was significantly down-regulated in cardiomyocytes treated with DSF. Finally, we also used experimental comparisons to indicate that PEG is a promising solvent for decreasing the adverse side effects of DSF, thereby expanding its potential range of clinical applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied Cardiomyocyte viability and apoptosis. Disulfiram (DSF) vs. Cancer cells was evaluated on Cardiomyocyte viability and apoptosis. Disulfiram inhibited cardiomyocyte viability and promoted apoptosis, with cardiomyocytes demonstrating greater sensitivity to the drug than cancer cells.
Synapse has enriched 10 related papers. Consider them for comparative context: